The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III, double-blind, placebo-controlled, crossover study evaluating a 5HT3 antagonist plus dexamethasone with or without aprepitant in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy: A Hoosier Oncology Group (HOG) study.
M. J. Brames
No relevant relationships to disclose
J. Picus
No relevant relationships to disclose
M. Yu
No relevant relationships to disclose
E. L. Johnston
No relevant relationships to disclose
B. Bottema
No relevant relationships to disclose
C. E. Williams
No relevant relationships to disclose
L. H. Einhorn
No relevant relationships to disclose